Citation

Dusouchet T, Bret MC, Bret P. Pharmacien Hospitalier 2006; 41(164): 25-31.

Copyright

(Copyright © 2006)

DOI

10.1016/S0768-9179(06)75347-0

PMID

unavailable

Abstract

After Specific Serotonine Reuptake Inhibitors arrived on the market, two new type of drugs appeared in antidepressant therapy, the Noradrenaline and Serotonine Reuptake Inhibitors (NaSRI) and the Noradrenergic and Serotonine Specific Antidepressants (NaSSA). Thanks to a specific activity on serotonine and/or noradrenaline systems, those three groups of medication appear to be easier to use and with less side effects than the older tricyclic drugs or the Mono Amine Oxydase Inhibitors. Nevertheless, each molecule has its own specificities which require precise usage recommendations. The purpose of this article is to go over the pharmacology of those three families of antidepressants, their pharmacokinetics, their specific characteristics and the precautions to observe while used with specific patients such as elderly people, pregnant women, drug users or teenagers. © Masson, Paris, 2006.

Language: fr

Keywords

human; suicide; Review; Antidepressive agents; depression; anxiety; lithium; treatment outcome; pregnancy; review; obesity; substance abuse; anorexia; vomiting; antidepressant agent; sexual dysfunction; drug metabolism; citalopram; cognitive defect; fluoxetine; fluvoxamine; monoamine oxidase inhibitor; paroxetine; sedation; serotonin uptake inhibitor; sertraline; tachycardia; venlafaxine; somnolence; sleep disorder; noradrenalin; practice guideline; dopamine; drug mechanism; clonidine; nonhuman; psychopharmacotherapy; treatment withdrawal; confusion; placebo; cannabis addiction; drug dependence; digoxin; drug receptor binding; serotonin receptor; nausea; tremor; weight gain; hypotension; naltrexone; drug utilization; Pharmacokinetics; high risk patient; hypertension; side effect; escitalopram; milnacipran; agitation; cytochrome P450 3A4; drug absorption; drug half life; drug contraindication; obsessive compulsive disorder; receptor upregulation; drug clearance; paresthesia; cocaine dependence; drug dose regimen; drug bioavailability; hyperthermia; cytochrome P450 1A2; cytochrome P450 2D6; visual disorder; narcotic dependence; triptan derivative; ejaculation disorder; hyperphagia; serotonin noradrenalin reuptake inhibitor; drug protein binding; creatinine clearance; cytochrome P450 2C19; muscarinic M3 receptor; Noradrenaline and serotonine reuptake inhibitors; Noradrenergic and serotonine specific antidepressants; receptor blocking; Specific serotonine reuptake inhibitors